MXPA03010523A - Anticuerpos especificos para cd44v6. - Google Patents

Anticuerpos especificos para cd44v6.

Info

Publication number
MXPA03010523A
MXPA03010523A MXPA03010523A MXPA03010523A MXPA03010523A MX PA03010523 A MXPA03010523 A MX PA03010523A MX PA03010523 A MXPA03010523 A MX PA03010523A MX PA03010523 A MXPA03010523 A MX PA03010523A MX PA03010523 A MXPA03010523 A MX PA03010523A
Authority
MX
Mexico
Prior art keywords
antibody
antibody proteins
cd44v6
antibodies specific
antibodies
Prior art date
Application number
MXPA03010523A
Other languages
English (en)
Spanish (es)
Inventor
J Miglietta John
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MXPA03010523A publication Critical patent/MXPA03010523A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MXPA03010523A 2001-05-18 2002-05-17 Anticuerpos especificos para cd44v6. MXPA03010523A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US23514701P 2001-09-26 2001-09-26
PCT/EP2002/005467 WO2002094879A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Publications (1)

Publication Number Publication Date
MXPA03010523A true MXPA03010523A (es) 2004-07-01

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010523A MXPA03010523A (es) 2001-05-18 2002-05-17 Anticuerpos especificos para cd44v6.

Country Status (18)

Country Link
EP (1) EP1397387A1 (enExample)
JP (1) JP2005504517A (enExample)
CN (1) CN1541226A (enExample)
AR (1) AR036154A1 (enExample)
BR (1) BR0210905A (enExample)
CA (1) CA2443437A1 (enExample)
CZ (1) CZ20033476A3 (enExample)
EA (1) EA200301169A1 (enExample)
EC (1) ECSP034838A (enExample)
EE (1) EE200300569A (enExample)
HU (1) HUP0400030A3 (enExample)
MX (1) MXPA03010523A (enExample)
PE (1) PE20021098A1 (enExample)
PL (1) PL365735A1 (enExample)
SK (1) SK15592003A3 (enExample)
WO (1) WO2002094879A1 (enExample)
YU (1) YU91403A (enExample)
ZA (1) ZA200307365B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
DK2167038T3 (en) * 2007-06-13 2018-08-06 Zymogenetics Inc USING TACI-IG FUSION PROTEIN AS ATACICEPT TO PREPARE A MEDICINE FOR TREATING LUPUS ERYTHEMATOSUS
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
AU2011212485B2 (en) 2010-02-04 2014-04-17 University Of Miami A monoclonal antibody to CD44 for use in the treatment of head and neck squamous cell carcinoma
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
JP2023516080A (ja) * 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
US20250326855A1 (en) * 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
WO1994012631A1 (en) * 1992-11-20 1994-06-09 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Also Published As

Publication number Publication date
EA200301169A1 (ru) 2004-06-24
CN1541226A (zh) 2004-10-27
PE20021098A1 (es) 2003-02-11
EE200300569A (et) 2004-04-15
CZ20033476A3 (cs) 2004-05-12
YU91403A (sh) 2006-05-25
AR036154A1 (es) 2004-08-18
EP1397387A1 (en) 2004-03-17
WO2002094879A1 (en) 2002-11-28
ECSP034838A (es) 2003-12-24
ZA200307365B (en) 2004-05-10
CA2443437A1 (en) 2002-11-28
HUP0400030A3 (en) 2006-02-28
PL365735A1 (en) 2005-01-10
BR0210905A (pt) 2004-06-08
HUP0400030A2 (hu) 2004-04-28
SK15592003A3 (sk) 2004-06-08
JP2005504517A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
MXPA03010523A (es) Anticuerpos especificos para cd44v6.
EP3660510A3 (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
ATE516047T1 (de) Ovr110-antikörperzusammensetzungen und anwendungsverfahren
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
UA92580C2 (ru) Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
EA200800094A1 (ru) Антитела cd19 и их использование
ATE420160T1 (de) Modifizierte rekombinante vacciniaviren, verwendungen davon
WO2007067991A3 (en) Human monoclonal antibodies to o8e
ATE382053T1 (de) System zur antikörperexpression und- synthese
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
WO2006076691A3 (en) Irta-2 antibodies and their uses
WO2005097185A3 (en) Irta-5 antibodies and their uses
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
ATE462726T1 (de) Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
ATE514718T1 (de) Peptabody für krebsbehandlung
AU2002252999A1 (en) Method of producing recombinant antibodies against tumors
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
AU2002318934A1 (en) Sak: modulation of cellular proliferation for treatment of cancer
UY27298A1 (es) Anticuerpos específicos de cd44v6
PT914417E (pt) Dnase ii humana